Sollinda Capital Management’s AbbVie ABBV Stock Holding History

Sollinda Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$553K	Sell	2,544 -112	-4%	-$24.8K	0.13%	44
2025 Q4	$607K	Sell	2,656 -8	-0.3%	-$1.82K	0.16%	44
2025 Q3	$617K	Sell	2,664 -12,759	-83%	-$2.6M	0.17%	39
2025 Q2	$2.86M	Buy	15,423 +12,407	+411%	+$2.31M	0.75%	17
2025 Q1	$632K	Sell	3,016 -115	-4%	-$22.4K	0.18%	33
2024 Q4	$556K	Buy	3,131 +123	+4%	+$22.6K	0.15%	33
2024 Q3	$594K	Buy	3,008 +49	+2%	+$9.14K	0.17%	34
2024 Q2	$508K	Buy	2,959 +53	+2%	+$8.78K	0.15%	36
2024 Q1	$529K	Sell	2,906 -1,431	-33%	-$247K	0.17%	32
2023 Q4	$672K	Buy	+4,337	New	+$632K	0.19%	30

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sollinda Capital Management's ABBV Position: Q1 2026 in Review

Sollinda Capital Management reduced its AbbVie (ABBV) stake by 4.2% in Q1 2026, selling an estimated $24.8K and leaving 2,544 shares worth $553K. The position accounts for 0.13% of the portfolio, ranked #44.

Sollinda Capital Management first reported a position in ABBV in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.86M in Q2 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Sollinda Capital Management held 2,544 shares of AbbVie worth $553K as of Q1 2026.
Sollinda Capital Management sold 112 AbbVie shares in Q1 2026, an estimated $24.8K.
AbbVie made up 0.13% of Sollinda Capital Management's portfolio in Q1 2026, its #44 holding.
Sollinda Capital Management first reported a position in AbbVie in Q4 2023 and has held it in 10 quarters since.
Sollinda Capital Management's AbbVie position peaked at $2.86M in Q2 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Sollinda Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.